Paper Details

  1. Home
  2. Paper Details

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Author: AmaravadiRavi K, BollagGideon, CockeyLouise, FlahertyKeith T, GilbertHouston N, GonzalezRene, HerseyPeter, HutsonThomas E, JoeAndrew K, KimKevin B, KockxMark, KoehlerAstrid, LawrenceDonald, LeeRichard J, LewisKarl D, LoRoger S, LongGeorgina V, McArthurGrant A, MoschosStergios J, OttPatrick A, PavlickAnna C, PuzanovIgor, RibasAntoni, Schell-StevenAnnette, SchuchterLynn, SosmanJeffrey A, SpleissOlivia, TrunzerKerstin, WeberJeffrey S

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase II study evaluated the pharmacodynamic effects and resistance mechanisms of the BRAF inhibitor vemurafenib in patients with BRAF(V600)-mutant melanoma. Vemurafenib effectively inhibited MAPK signaling and cell-cycle progression. However, acquired resistance was observed in some patients due to MAPK reactivation driven by secondary mutations in NRAS and MEK1. These findings suggest that inhibition downstream of BRAF may help overcome resistance.
Paper Details　
Original Abstract of the Article :
PURPOSE To assess pharmacodynamic effects and intrinsic and acquired resistance mechanisms of the BRAF inhibitor vemurafenib in BRAF(V600)-mutant melanoma, leading to an understanding of the mechanism of action of vemurafenib and ultimately to optimization of metastatic melanoma therapy. METHODS In ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2012.44.7888

データ提供：米国国立医学図書館（NLM）

Vemurafenib Resistance in Melanoma: A Journey Through the Desert of Resistance

[Cancer treatment] is a complex and challenging field, with [Drug resistance] being a major obstacle to successful treatment. This study explores the [Pharmacodynamic effects] and [Resistance mechanisms] of [Vemurafenib], a targeted therapy for [BRAF(V600)-mutant melanoma]. It’s like navigating a vast desert, encountering various obstacles and adaptations in the path to cancer eradication. The researchers found that [Vemurafenib] effectively inhibited [MAPK signaling] and [Cell-cycle progression] in melanoma cells, leading to tumor shrinkage in some patients. However, they also observed the emergence of [Acquired resistance] in some cases, highlighting the need for [New strategies] to overcome this challenge. The study suggests that [Inhibition downstream of BRAF] could potentially overcome acquired resistance, offering a new path through the desert of resistance.

A Shifting Landscape: Understanding and Overcoming Vemurafenib Resistance

The study reveals the complex interplay between [Cancer cells] and [Targeted therapies], showcasing the need for [Continued research and development] to overcome [Drug resistance]. It’s like discovering a hidden oasis in the desert, offering a source of hope for patients facing the challenges of [Melanoma]. The findings suggest that targeting [Downstream pathways] could potentially circumvent resistance mechanisms, offering a new avenue for [Effective treatment].

Navigating the Desert of Melanoma Treatment: A Constant Quest for Innovation

This study underscores the ongoing need for [Innovation and collaboration] in [Cancer research]. It emphasizes the importance of [Understanding the mechanisms of resistance] to develop [More effective and durable treatments]. It’s like gathering knowledge and resources in the desert, preparing for the challenges ahead, and ensuring a better future for patients battling [Melanoma].

Dr.Camel's Conclusion

This study provides valuable insights into the pharmacodynamic effects and resistance mechanisms of vemurafenib in melanoma. The findings highlight the challenges posed by drug resistance but also offer hope for the future with the potential of overcoming resistance by targeting downstream pathways.

Date :
  1. Date Completed 2013-07-01
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

23569304

DOI: Digital Object Identifier

10.1200/JCO.2012.44.7888

Related Literature

Article Analysis
・Effects of vemurafenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.